Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma
|ClinicalTrials.gov Identifier: NCT03376958|
Recruitment Status : Completed
First Posted : December 19, 2017
Last Update Posted : July 25, 2019
|Condition or disease||Intervention/treatment||Phase|
|Relapsed and Refractory Diffuse Large B Cell Lymphoma||Drug: Apatinib||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||32 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study|
|Actual Study Start Date :||January 1, 2017|
|Actual Primary Completion Date :||February 1, 2019|
|Actual Study Completion Date :||April 30, 2019|
Apatinib 500mg once daily makes an initial dose and 28 days made one treatment cycle. All patients took the drug continuously until disease progression, intolerable toxicities, and patient-requested withdrawal. Appropriate supportive care were given.
Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.
- Overall Response Rate [ Time Frame: up to end of follow-up-phase ]The proportion of patients whose tumor volume has reduced to a predetermined value and can maintain the minimum time limit is the sum of complete and partial mitigation.
- Progression-free Survival [ Time Frame: up to end of follow-up-phase ]The time between the start of randomization and the progression of the tumor (any aspect) or (for any reason) death
- Overall Survival [ Time Frame: up to the date of death or end of follow-up-phase ]Time from randomization to death for any reason
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03376958
|Oncology Department of The First Affiliated Hospital of Zhengzhou University|
|Zhengzhou, Henan, China, 450052|